伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察

来源期刊：广州医药 | 489-493 发布时间：2024-06-28 收稿时间：2025/11/17 15:49:19 阅读量：26

作者：: 李思荃,

蔡祥胜,

张伟铮,

胡笑仪,

孙宁,

许研,

关键词：: 伏诺拉生阿莫西林呋喃唑酮幽门螺杆菌三联疗法; vonoprazan amoxicillin furazoldone Helicobacter pylori triple therapy

DOI：: 10.3969/j.issn.1000-8535.2024.05.006

收稿时间：: 2024-01-03
修订日期：
接收日期：
引用总数：: 3

目的探究伏诺拉生三联疗法根除幽门螺杆菌（Hp）的疗效。方法入组2022年5月—12月经¹³C尿素呼气试验确诊的Hp现症感染者200例,分为观察组和对照组,每组100例。观察组方案为阿莫西林、呋喃唑酮、伏诺拉生三联疗法,对照组方案为阿莫西林、呋喃唑酮、艾司奥美拉唑镁、枸橼酸铋钾四联疗法;疗程均为14 d。在治疗停药后1个月复查¹³C尿素呼气试验判定是否Hp根除成功,并观察药物不良反应发生率。结果观察组Hp根除率为96.97%,高于对照组的89.80%,差异有统计学意义（P<0.05）;观察组不良反应发生率和对照组比较差异无统计学意义（P>0.05）。结论伏诺拉生、阿莫西林、呋喃唑酮三联疗法的Hp根除率较高且安全性良好,可作为Hp感染的治疗方案之一。

1、王丽娜,张田,曹娅,等.伏诺拉生根除幽门螺杆菌感染的快速卫生技术评估[J].临床药物治疗杂志,2022,20(10):17-22.

2、王先令,周国强,林琳,等.伏诺拉生联合阿莫西林、克拉霉素三联七日疗法根除幽门螺杆菌的临床研究[J].实用医学杂志,2022,38(10):1271-1275.

3、陈剑. 伏诺拉生与阿莫西林二联治疗幽门螺杆菌感染胃溃疡的疗效和安全性[J].中国实用医药,2021,16(1):125-127.

4、 MARUYAMA M,TANAKA N,KUBOTA D,et al.Vonoprazan-based regimen is more useful than PPI-based one as a first-line helicobacter pylori eradication:A randomized controlled trial[J].Can J Gastroenterol Hepatol,2017(2017):4385161.

5、 SUE S,SUZUKI N,SHIBATA W,et al.First-line helicobacter pylori eradication with vonoprazan,clarithromycin,and metronidazole in patients allergic to penicillin[J].Gastroenterol Res Pract,2017(2017):2019802.

6、 GUNARATNE A W,HAMBLIN H,CLANCY A,et al.Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study[J].Helicobacter,2021,26(5):e12830.

7、 DONG S Q,SINGH T P,WEI X,et al.Review:A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy:Is superiority an illusion?[J].Helicobacter,2017,22(6).

8、 YAMASAKI H,KAWAGUCHI N,NONAKA M,et al.In vitro metabolism of TAK-438,vonoprazan fumarate,a novel potassium-competitive acid blocker[J].Xenobiotica,2017,47(12):1027-1034.

9、 OTAKE K,SAKURAI Y,NISHIDA H,et al.Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate(TAK-438)[J].Adv Ther,2016,33(7):1140-1157.

10、 SAKURAI Y,NISHIMURA A,KENNEDY G,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of single rising TAK-438(vonoprazan)doses in healthy male Japanese/non-Japanese subjects[J].Clin Transl Gastroenterol,2015,6(6):e94.

11、 MIFTAHUSSURUR M,PRATAMA PUTRA B,YAMAOKA Y.The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy[J].Pharmaceuticals(Basel),2020,13(10):276.

12、 FURUTA T,SHIRAI N,SUGIMOTO M,et al.Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies[J].Drug Metab Pharmacokinet,2005,20(3):153-167.

13、 SAKURAI Y,MORI Y,OKAMOTO H,et al.Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study[J].Aliment Pharmacol Ther,2015,42(6):719-730.

14、 IERARDI E,LOSURDO G,FORTEZZA R F,et al.Optimizing proton pump inhibitors in Helicobacter pylori treatment:Old and new tricks to improve effectiveness[J].World J Gastroenterol,2019,25(34):5097-5104.

15、何小琦,罗承锋,刘月婵,等.中西医结合治疗HP相关性慢性胃炎的疗效分析[J].广州医药,2006(3):77-78.

16、周昱. 慢性胃炎合并Hp感染应用香砂六君子汤联合基础三联治疗的效果[J].中国医药科学,2023,13(22):85-88,128.

17、彭卫斌,容海鹰,沙卫红,等.含益生菌四联疗法根除幽门螺杆菌的临床疗效[J].广州医药,2017,48(1):38-41.

18、中华医学会消化病学分会幽门螺杆菌学组.第六次全国幽门螺杆菌感染处理共识报告(非根除治疗部分)[J].中华消化杂志,2022,42(5):289-303.

19、国家消化系疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟(GECA),中华医学会消化病学分会幽门螺杆菌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华消化杂志,2019,39(5):310-316.

20、 TANABE H,ANDO K,SATO K, et al.Efficacy of vonoprazan-based triple therapy for helicobacter pylori eradication:A multicenter study and a review of the literature[J].Dig Dis Sci,2017,62(11):3069-3076.

21、 MARTIN,ZHOU Y,MENG C X,et al.Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding:A meta-analysis of randomized controlled trials and observational studies[J].Medicine(Baltimore).2020,99(9):e19357.

22、 KATO M,OTA H,OKUDA M,et al.Guidelines for the management of Helicobacter pylori infection in Japan:2016 Revised Edition[J].Helicobacter,2019,24(4):e12597.

23、屈健,奉继运,张文达.三联疗法治疗幽门螺旋杆菌感染消化性溃疡的临床分析[J].广州医药,2010,41(6):27-28.

24、李超,徐晓军,孔超美,等.幽门螺杆菌根除前及根除失败后耐药情况分析[J].胃肠病学和肝病学杂志,2022,31(4):383-385,396.

25、刘文忠,谢勇,陆红,等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2017,22(6):346-360.

1、萨础拉.大剂量阿莫西林二联方案与常规四联方案治疗幽门螺杆菌感染的疗效观察[D].内蒙古民族大学,2025.DOI:10.27228/d.cnki.gnmmu.2025.000350.

2、魏建昌,何杭晶,陈转鹏,等.成人全麻腹腔镜下疝修补日间手术可行性和安全性分析[J].广州医药,2024,55(11):1357-1362+1380.DOI:10.20223/j.cnki.1000-8535.2024.11.019.

3、王爽,周丽娟,张玮,等.伏诺拉生根治东亚人群幽门螺杆菌感染有效性及安全性的网状Meta分析[J].中国医院药学杂志,2025,45(16):1886-1894.DOI:10.13286/j.1001-5213.2025.16.11.